SAN DIEGO, Jan. 31 /PRNewswire/ -- MedWaves, Inc. announces the receipt of USFDA 510k clearance to market its patented Microwave Coagulation/Ablation System for general surgery use for the coagulation and ablation of soft tissues. The system is comprised of a microwave generator and single patient use sterile devices. The clearance sets the stage for rapid expansion of a product portfolio and indications for use through additional USFDA submissions and clearances. The Company's proprietary technology allows for the development of minimally invasive devices in wide range of sizes, shapes and flexibility to meet clinicians' requirements in bone, liver, lung and other tumors.
About The Avecure(TM) Ablation System
MedWaves Microwave Coagulation/Ablation System overcomes limitations of existing microwave and radiofrequency (RF) thermal ablation technologies, the standard of treatment for oncology patients who are not candidates for surgery. Initially the Company focused on the general use of its coagulative technology with a high percentage of the anticipated use in patients with bone, liver and lung tumors. For these patients, adjunctive use of microwave ablation can assist in the curative and/or palliative goals of standard therapies e.g. chemotherapy and/or radiation. It can be an option for patients where other thermal modalities are not possible due to tumor size or location.
press release >> http://sev.prnewswire.com/health-care-hospitals/20080131/LATH11331012008-1.html
No comments:
Post a Comment